Please upgrade your browser.
We recently polled the more than 67,000 members of our Facebook community about the Affordable Care Act.
Unfavorable views of the law still outnumber favorable ones by a substantial margin.
WSJ: Employee Benefit Research Institute CEO Dallas Salisbury says health care costs - not income - is the ticking time bomb for American retirees, saying "the long term care private insurance market is essentially collapsing."
By Michael B. Lawing
microRNA assay determined reasonable and necessary for providing an important niche in pathologic diagnoses of Cancer of Unknown Primary.
The FDA has approved more than 30 molecularly targeted agents in cancer in recent years, including prominent examples such as trastuzumab for breast cancer, sunitinib for renal cell cancer and bevacizumab for colorectal, non-small cell lung and renal cell cancers.
Argos Therapeutics Announces US And Global Expansion For Ongoing Pivotal Phase 3 ADAPT Study For Personalized Immunotherapy
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, has announced it has expanded its ADAPT Phase 3 clinical study for AGS-003 to additional top cancer centers in the United States, Canada and will soon be expanding into Europe and Israel.
Threshold Pharmaceuticals, Inc., a biotechnology company, has announced data from two ongoing Phase I/II trials evaluating TH-302, an investigational hypoxia-targeted drug, in patients with relapsed/refractory multiple myeloma and gastrointestinal stromal tumors and renal cell carcinoma.
Meagan Blackmore was diagnosed with stage four kidney cancer at the age of 30. This June 20th fundraiser event in Albany, NY will help raise money to help Megstrong and Meagan's fight against kidney cancer. For more information on this event or this organization, please visit: http://www.megstrong.com/
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseasesusing its Arcelis(TM) technology platform, today announced it has expanded its ADAPT Phase 3 clinical study for AGS-003.
|Powered by NeonCRM|